Edwards Sells LifeStent Peripheral Business To Bard For $140 Million
Edwards Lifesciences is giving up on the peripheral vascular market to focus its resources on its heart valve and critical care businesses
Edwards Lifesciences is giving up on the peripheral vascular market to focus its resources on its heart valve and critical care businesses